Consortium


Coordinator

Ondrej Slaby is a research group leader in CEITEC (Central European Institute of Technology, Masaryk University, Brno, CZ) and in his research he is focused on comprehensive and high-throughput analysis of non-coding RNAs, mainly RNAseq and small RNAseq, in solid cancer and identification of potential susceptibility, diagnostic, prognostic, and predictive biomarkers in tumor tissue or patient’s body fluids and development of related intellectual property.

CEITEC is a unique research center focusing primarily on the fields of life sciences, advanced materials and nanotechnologies. Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

Partner


George A. Calin is Professor at Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA and is focused mainly on the involvement of non-coding RNAs in human diseases in general and of microRNAs in human cancers in particular, the study of familial predisposition to human cancers, the identification of ncRNA biomarkers in body fluids, and the development of new RNA-based therapeutic options for cancer patients.

MD Anderson Cancer Center (MDACC) is one of the largest cancer centers in the world and has been working to eliminate cancer for more than seven decades. Moreover, MDACC has ranked as one of the top two hospitals in cancer care every year since U.S. News & World Report began its annual “America’s Best Hospitals” survey in 1990. MDACC is world-renowned for using and developing front-line diagnostic technology. That lets physicians pinpoint each patient’s unique cancer and tailor treatment for the best possible outcome.

Participants

Martin Pichler is head of Research Unit for Non-Coding RNA and Genome Editing in Cancer Department of Internal Medicine, Division of Oncology Comprehensive Cancer Center Graz, Medical University of Graz, Austria. His main research areas are the involvement and consequences of altered expression of non-coding RNAs including microRNAs and long non-coding RNAs in human cancer with a particular focus on colorectal, breast and kidney cancer, and Clinical Outcome Research and personalized biomarker studies on large datasets of human cancer.

Medical University of Graz provides innovative and practical training, forward-looking and excellent research, and first class and personalised patient care. New findings regarding the causes of disease, development of preventive measures and working out new treatments are a mark of the success of medical research in Graz.

Ioana Berindan Neagoe is a director of Research Center for Functional Genomics, Biomedicine and Translational Medicine at Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Research Center for Functional Genomic, Biomedicine and Translational Medicine has been established in 2010, with a new space of 1400 square meters, finalized in 2014. The concept of the state-of-art research center was to put together research laboratories and core facilities able to develop projects related to human diseases, at molecular and cellular level. All together: talented researchers, postdocs, Ph.D. students, undergraduate young minds, high throughput technologies and research ideas make the Genomic Center a new facility for research and training in the Iuliu Hațieganu University of Medicine and Pharmacy.

Klaus Pantel is chairman of the Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Centre Hamburg. The research of Prof. Pantel’s group is based on the aim to detect cancer cells and its components as DNA and microRNA using high sensitive procedures and to decode its properties using molecular biological methods. This research known as "liquid biopsy" is important for the evaluation of the prognosis of patients with breast cancer and other carcinoma, e.g. prostate, colon or lung cancer. It indicates to special targeted therapies and enables early assessment of the success or fail of therapy. Furthermore, our more basic research investigates the process of the dissemination of tumor cells and the metastases as the main reason for malignancy of cancer. Altogether, these research activities will contribute to the development of innovative cancer therapies in the future.

The Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf was founded in 2002 to bridge between basic research and the clinic. Translational research conducted in our laboratory aims at a better understanding of the molecular mechanisms underlying cancer development and progression, improved cancer diagnostics and also treatment of cancer patients, with a particular emphasis on so called ‘targeted therapies’.

Massimo Negrini is an associate professor at the Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy.

The University of Ferrara Medical Sciences research is focused mainly on prevention, treatment and cure of human diseases. The research lines are focused on (i) epidemiology, (ii) clinical trials, (iii) studies of clinical-pathologic correlation, (iv) development of markers of susceptibility and predictive for early diagnosis, and markers of progression and aggressiveness (biological and genetic profiling) as a tool for clinical correlation for predicting the potential evolutionary of disease, also in relation with methods of treatment (correlation with molecular and biological parameters of the control of the disease with drug therapy, and biological, radiological and radiobiological therapy), (v) improvement of knowledge in genetics, epigenetics, cellular and molecular biology underlying the etiology/etiopathogenesis, also in association with exposure to environmental risk factors (physical, chemical and infectious agents), (vi) development of procedures for surgery in the field of oncology, orthopedics, dentistry, otolaryngology and maxillofacial, and implementation of biomedical technologies functional to surgery, and radiological and medical therapy.


BioVendor Group is an international diagnostics company with its headquarters in Brno, Czech Republic.

BioVendor provides a broad range of IVD technologies and capabilities including, in-house development and manufacturing of immunoassays and molecular diagnostics for the clinical market, as well as a wide offering for the Life Sciences market.

The core of the portfolio consists of immunoassays in several formats, both single-test and multiplexed. The portfolio is focused on infectious serology, autoimmunity, endocrinology, and newly-discovered biomarkers.

Since its establishment in 1992, BioVendor has placed high importance on innovation and value brought to customers via providing diagnostics solutions. Recent examples include fully automated ELISA platform, proprietary microarray solution, Next Generation Sequencing kits, and proprietary miRNA immunoassays.

BioVendor is committed to its strategy to grow internationally. BioVendor has an extensive track record of acquisitions including, TestLine Clinical Diagnostics (Czech Republic), ViennaLab Diagnostics (Austria), Oxford Biosystems (UK), and most recently in September 2017, DIAsource Immuno-Assays (Belgium).


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 824036.
Disclaimer: This website and included materials reflect only the author’s view and the Research Executive Agency is not responsible for any use that may be made of the information it contains.